Immatics to present three PRAME programs at ESMO 2026, signaling pipeline momentum
Jul 17, 2026, 10:27 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Conference-driven data readouts, especially positive durability signals across multiple PRAME programs, have historically acted as near-term catalysts for biotech names. While Phase 1 data are early, multiple presentations at a premier congress and a broad PRAME slate increase odds of favorable sentiment shifts and potential multiple expansion if data look durable.
AI summary
What happened, with direct paths to the underlying reporting
Immatics will showcase three PRAME data sets at ESMO 2026 in Madrid (Oct 23-27). The program includes anzucel phase 1b melanoma data, IMA203CD8 Phase 1 across PRAME-positive tumors with gynecologic durability, and IMA402 PRAME bispecific at RP2D across multiple cancers, supporting expansion and combination studies.
Immatics to present three PRAME data programs at ESMO 2026. Abstracts published Oct 19.
Phase 1b anzucel data in metastatic melanoma highlighted. Focus on durable response predictors.
IMA203CD8 phase 1 across PRAME-positive tumors; gynecologic durability dose follow-up.
IMA402 PRAME bispecific at RP2D; expansion cohorts and combos.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Immatics N.V. initiated a $150 million public offering. Updated Phase 1b data shows IMA203 effective in melanoma patients. No Grade 5 adverse events reported in IMA203 treatment.…
